Get started
Work

P0848 : Efficacy of response-guided pegylated interferon and ribavirin therapy for people who inject drugs with HCV genotype 2/3 infection: The activate study

Year: 2015
Type: article
DOI: 10.1016/s0168-8278(15)31050-3
Authors: J. Grebely, O. Dalgard, B. Conway, G. Foster, P. Bruggmann, M. Backmund, G. Robaeys, T. Swan, B. Hajarizadeh, J. Amin, P. Marks, S. Quiene, M. Weltman, D. Shaw, A. Dunlop, M. Hellard, J. Bruneau, S. Bourgeois, C. Thurnheer, G.J. Dore
Institutions: UNSW Sydney, Kirby Institute, Akershus University Hospital, Vancouver Infectious Diseases Centre, Queen Mary University of London, Arud, Ludwig-Maximilians-Universität München, Universitair Ziekenhuis Leuven, Ziekenhuis Oost-Limburg, Hasselt University, Treatment Action Group, Nepean Hospital, Royal Adelaide Hospital, University of Newcastle Australia, Burnet Institute, Université de Montréal, Ziekenhuisnetwerk Antwerpen Stuivenberg, University of Bern, University Hospital of Bern
Language: English
Subfield: Hepatology
Field: Medicine
Open Access status: green
OpenAlex ID: W2504624206
FWCI:
Cites:
Cited by:
Related to: 10